Shots:
- Sensome has reported results from its INSPECT study assessing its microsensor technology integrated into a smart stylet for bronchoscopic lung biopsy in 27 pts across Australia & France
- In the study, the smart stylet was inserted into the biopsy needle to capture tissue readings immediately before biopsy, with histopathology confirming measurement accuracy & cross-validating the results
- Smart stylet differentiated cancer from healthy & necrotic tissue, achieving 80.9% accuracy in distinguishing healthy from abnormal lung tissue (88.5% sensitivity; 71.4% specificity) & 78.7% accuracy in differentiating cancer from all other tissues (78.3% sensitivity; 79.2% specificity); data were presented at ATS’26
Ref: Businesswire | Image: Sensome | Press Release
Related News: Sunrise Group Wins the US FDA Clearance for Sunrise Air Home Sleep Apnea Test
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
